ESR1 and breast cancer: Moreover, estrogen binding to the ER, promotes the cell cycle progression of HR+ breast cancer cells [8, 9] while ER antagonists (fulvestrant) have been reported to inhibit estrogen’s mitogenic activity on the cell cycle [10–12].